MGTX$9.48
$9.20
Chart
Performance
Key Stats
AI MGTX Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
NeutralMeiraGTx Holdings plc shows potential in its clinical pipeline but faces significant financial challenges and negative earnings. Technical indicators are mixed, suggesting a cautiously neutral stance.
Thematic
MeiraGTx operates in the promising field of gene therapies, targeting serious diseases. However, the company is still in the clinical stage, meaning its success is tied to regulatory approvals and clinical trial outcomes.
Fundamental
MeiraGTx exhibits significant negative earnings and a substantial net loss, indicating ongoing cash burn. While current assets outweigh current liabilities, the overall financial health requires careful monitoring due to high operating expenses.
Technical
The stock has experienced a significant downward trend over the past year, with short-term indicators showing mixed signals. Key moving averages are predominantly below the current price, indicating a bearish sentiment.
| Factor | Score |
|---|---|
| Gene Therapy Market Growth | 80 |
| Pipeline Strength & Diversification | 70 |
| Clinical Trial Success Rate | 50 |
| Partnerships & Collaborations | 75 |
| Regulatory Landscape | 55 |
| Factor | Score |
|---|---|
| Valuation | 30 |
| Profitability | 5 |
| Growth | 70 |
| Balance Sheet Health | 70 |
| Cash Flow | 15 |
| Debt Level | 40 |
| Factor | Score |
|---|---|
| Trend Analysis | 70 |
| Momentum | 60 |
| Moving Averages | 75 |
| Support & Resistance | 50 |
| Volume Confirmation | 50 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Innovative Therapies for Serious Diseases
MeiraGTx Holdings plc is a clinical-stage company focused on developing gene therapies for serious diseases, including inherited retinal diseases, neurodegenerative diseases, and xerostomia. Its pipeline includes AAV-based therapies in various stages of clinical trials, demonstrating a commitment to addressing unmet medical needs.
Strong Recent Performance
The stock has shown significant positive performance over multiple periods, with a 6-month return of 33.82% and a 1-year return of 63.44%. Year-to-date performance is also strong at 31.90%.
Bearish Points (8)
Consistent Net Losses
The company has consistently reported net losses. For example, in 2024 (TTM), the net income was -$118.71 million. This is common for clinical-stage biotech companies, but represents a significant risk until commercialization.
Negative P/E Ratio
The trailing Price-to-Earnings (P/E) ratio is negative (-5.6 TTM), indicating the company is not currently profitable on a per-share basis. The Price-to-Sales (P/S) ratio is also high at 19.4 TTM, reflecting the early-stage nature of the business.
Calendar
August 2025
11
Next Earnings Date
H: $
A: $
L: $
H: 16.70M
A: 6.48M
L: 1.93M
Profile
MeiraGTx Holdings plc, a clinical stage genetics medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also developing AAV-AQP1 in Phase 2 trial for radiation-induced grade 2/3 radiation-induced xerostomia, as well as in Phase ½ trial for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase 2 trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.
Seasonals
Price Target
27.50 USD
The 39 analysts offering 1 year price forecasts for MGTX have a max estimate of 50.00 and a min estimate of 13.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Leading cloud-native endpoint and workload protection, a direct competitor in the broader enterprise cybersecurity space that MGTX operates in.
Weight: 92
Specializes in cloud security, secure access service edge (SASE), and zero trust architecture, key areas of modern cybersecurity that align with data protection needs.
Weight: 90
Pioneer in identity and access management (IAM), crucial for enterprise data security and controlled access, which complements MGTX's data solutions.
Weight: 88
Comprehensive cybersecurity platform covering network, cloud, and security operations, representing a major player and benchmark in the field MGTX is involved with.